R.grid, London (2026)

22/09/2026

𝗧𝗵𝗲 𝗿𝗲𝗮𝗹 𝗽𝗿𝗼𝗺𝗶𝘀𝗲 𝗼𝗳 𝗔𝗜 𝗶𝘀𝗻’𝘁 𝘀𝗺𝗮𝗿𝘁𝗲𝗿 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆. 𝗜𝘁’𝘀 𝗯𝗲𝘁𝘁𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗯𝗲𝘁𝘁𝗲𝗿 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, 𝗮𝗻𝗱 𝗯𝗲𝘁𝘁𝗲𝗿 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲.

𝘚𝘤𝘢𝘭𝘪𝘯𝘨 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴: 𝘵𝘸𝘰 𝘣𝘪𝘨 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘸𝘦 𝘴𝘢𝘸 𝘢𝘵 𝘋𝘗𝘩𝘢𝘳𝘮:

𝟭. 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗽𝗿𝗼𝗳𝗶𝗹𝗲 𝗼𝗳 𝗔𝗜 𝗯𝗲𝗶𝗻𝗴 𝗲𝘅𝗮𝗺𝗶𝗻𝗲𝗱:
There's a lot of discussion from vendors about how they use AI and various approaches.

The opportunity now is to build greater shared understanding of what these methodologies mean for scientific research, and how we can evaluate their safety, reliability and suitability for clinical trials.

𝟮. 𝗕𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗻𝗲𝘄 𝗔𝗜 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘃𝗲𝗻𝗱𝗼𝗿𝘀 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗔𝗜 𝗺𝗼𝗱𝗲𝗹𝘀

There's opportunity to establish new ways of working, bridging scientific rigour and technological innovation.

This includes asking new questions about AI architecture, governance, data, and ownership, to rethink how clinical research is designed and delivered in the AI era.

𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗮𝗻𝗱 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝘄𝗶𝗹𝗹 𝗱𝗲𝗽𝗲𝗻𝗱 𝗼𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗼𝗻 𝗵𝗼𝘄 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆, 𝗽𝗲𝗼𝗽𝗹𝗲, 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝘄𝗼𝗿𝗸 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿.

21/09/2026

𝗙𝗿𝗼𝗺 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝘁𝗼 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘁𝗿𝗶𝗮𝗹𝘀: 𝘄𝗵𝗲𝗿𝗲 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝘀 𝗺𝗼𝘃𝗶𝗻𝗴

For 𝗪𝗼𝗿𝗹𝗱 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗗𝗮𝘆, we’re looking at how advances in 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻, 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗱𝗲𝘀𝗶𝗴𝗻 are shaping the next phase of Alzheimer’s research.

An 𝗲𝘀𝘁𝗶𝗺𝗮𝘁𝗲𝗱 𝟱𝟳 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗽𝗲𝗼𝗽𝗹𝗲 were living with dementia globally since 2021. 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗰𝗼𝗺𝗺𝗼𝗻 𝗳𝗼𝗿𝗺 𝗼𝗳 𝗱𝗲𝗺𝗲𝗻𝘁𝗶𝗮 𝗮𝗻𝗱 𝗺𝗮𝘆 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲 𝘁𝗼 𝟲𝟬–𝟳𝟬% 𝗼𝗳 𝗱𝗲𝗺𝗲𝗻𝘁𝗶𝗮 𝗰𝗮𝘀𝗲𝘀.

As of March 2025, the National Institute on Aging reported 466 active clinical trials and studies for Alzheimer’s and related dementia, spanning drug development, diagnostics, imaging, prevention, caregiving, and disease mechanisms.

The latest focus of clinical research is increasingly examining Alzheimer's disease at earlier stages, using biomarkers and imaging to:
• identify biological changes
• improve precision medicine
• improve treatment evaluation

The goal is not simply to develop more treatments, but to better understand what works, for whom, and at what stage of the disease.

18/09/2026

𝗪𝗲'𝗿𝗲 𝗯𝗮𝗰𝗸 𝗳𝗿𝗼𝗺 𝗗𝗣𝗵𝗮𝗿𝗺 𝟮𝟬𝟮𝟲! 𝗛𝗲𝗿𝗲'𝘀 𝗼𝘂𝗿 𝗣𝗮𝗿𝘁 𝟭 𝗿𝗲𝗰𝗮𝗽!

𝘛𝘩𝘦𝘮𝘦𝘴 𝘵𝘩𝘢𝘵 𝘴𝘵𝘰𝘰𝘥 𝘰𝘶𝘵:
𝟭. 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗔𝗜 𝘂𝘀𝗲 𝗰𝗮𝘀𝗲𝘀 𝗮𝗻𝗱 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗵𝘂𝗺𝗮𝗻 𝗰𝗵𝗲𝗰𝗸𝗽𝗼𝗶𝗻𝘁𝘀 - AI is being tested incrementally across several research use cases, but core work in understanding when it has very high impact, versus incremental progress is only being done by a few. In most cases, human intervention is still required and a standard way to check the accuracy of AI outputs.

𝟮. 𝗖𝗼𝗻𝗻𝗲𝗰𝘁𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 - we're still seeing a growing demand for more connected approaches. While many solutions focus on individual functions, Research Grid brings unified, end-to-end automation across the clinical trial lifecycle.

Thank you to everyone who connected with the Research Grid team and shared perspectives modernizing the industry.

10/09/2026

𝗠𝗲𝗻𝘁𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝘁𝗿𝗶𝗮𝗹𝘀 𝗱𝗲𝗽𝗲𝗻𝗱 𝗼𝗻 𝗵𝗶𝗴𝗵-𝗿𝗶𝘀𝗸 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗻𝗴 𝘀𝗮𝗳𝗲𝗹𝘆.

Su***de in particular accounts for more than 720,000 deaths globally each year, with 73% occurring in low- and middle-income countries.

In psychiatric research, restrictive eligibility criteria can exclude people with comorbidities, substance use, or su***de risk. This difficulty in protocol design creates study populations that may not fully reflect the patients seen in real-world care, which can limit the generalizability of clinical-trial findings.

On 𝗪𝗼𝗿𝗹𝗱 𝗦𝘂𝗶𝗰𝗶𝗱𝗲 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝗗𝗮𝘆, we look at how inclusive trial design and respectful and safe data practices can break down barriers and make mental health research safer and more accessible for everyone. Some of these include:

• 𝗠𝗼𝗱𝗲𝗿𝗻𝗶𝘇𝗶𝗻𝗴 𝘀𝘁𝘂𝗱𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝘀 using AI to address trial barriers
• 𝗦𝘁𝗿𝗲𝗮𝗺𝗹𝗶𝗻𝗶𝗻𝗴 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁 𝗶𝗻𝘁𝗮𝗸𝗲 and widening access through supportive AI and digital touch points
• Using 𝗽𝗿𝗶𝘃𝗮𝗰𝘆-𝗳𝗶𝗿𝘀𝘁 𝗮𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁𝘂𝗿𝗲 for secure and hybrid, or decentralized, capture of sensitive mental health data
• Enabling 𝗮𝗱𝗮𝗽𝘁𝗶𝘃𝗲 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 with remote monitoring to expand geographic reach without increasing administrative burden at the site level.

We support studies using these best practices and more to improve the success of even the most difficult trials.

See the resources in the comments for more information.

09/09/2026

We're at 𝗗𝗣𝗛𝗔𝗥𝗠 again this year on 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝟱–𝟭𝟲 in Boston, 𝗕𝗼𝗼𝘁𝗵 #𝟱𝟬𝟯!

We’re looking forward to connecting with industry leaders, exchanging perspectives, and exploring the future of clinical trials.

On Sept 15th we’ll be presenting practical AI-native in approaches for future-proofing your trials in Constitution A (Track 1A) at 11:45am.

Come say hello! We’d love to connect and discuss automating trials.

08/09/2026

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁 𝗔𝗜 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝘀𝗮𝗳𝗲𝗹𝘆, 𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁𝗹𝘆, 𝗮𝗻𝗱 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲?

We'll be sharing our thoughts on the topic, 𝗻𝗲𝘅𝘁 𝗧𝘂𝗲𝘀𝗱𝗮𝘆 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝟱𝘁𝗵 𝗮𝘁 𝟭𝟭:𝟰𝟱𝗮𝗺 𝗮𝘁 𝗗𝗣𝗵𝗮𝗿𝗺 𝗶𝗻 𝗖𝗼𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻 𝗔 (𝗧𝗿𝗮𝗰𝗸 𝟭𝗔).

Hear real-world case examples of how sponsors, CROs, and sites are using AI-native eClinical solutions to reduce administrative burden, improve data quality, and accelerate trial ex*****on while maintaining compliance and oversight.

𝗧𝗮𝗸𝗲-𝗮𝘄𝗮𝘆𝘀:
• Practical, unified or modular approaches, for safe, scalable, & compliant AI use
• Learn important questions to ask when choosing AI vendors
• Discover ways to gather internal support for implementing AI in your trials

If you're attending DPHARM 2026, join Dr. Hill and our team for the conversation or afterward at Booth 503.

03/09/2026

𝗧𝗵𝗲 𝗵𝗶𝗱𝗱𝗲𝗻 𝗯𝗼𝘁𝘁𝗹𝗲𝗻𝗲𝗰𝗸𝘀 𝘀𝗹𝗼𝘄𝗶𝗻𝗴 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝘁𝗼𝗱𝗮𝘆 𝗮𝗿𝗲 𝘄𝗲𝗹𝗹 𝗸𝗻𝗼𝘄𝗻 𝗯𝘂𝘁 𝘄𝗲 𝗮𝗿𝗲 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗿𝗼𝗻𝗴 𝗱𝗶𝗿𝗲𝗰𝘁𝗶𝗼𝗻.

Clinical trials exist to advance medicine. However 90% of trials are still failing.

The industry has historically accepted this as "scientific challenges" or "the cost of doing research". That's outdated reasoning.

Most clinical trials still rely on legacy systems, fragmented workflows, and manual back-office processes.

𝗬𝗲𝘁, 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗵𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝘂𝘀𝗲𝗱 𝗳𝗼𝗿 𝗼𝘃𝗲𝗿 𝟮𝟱 𝘆𝗲𝗮𝗿𝘀 𝗮𝗻𝗱 𝗳𝗼𝗿 𝗼𝘃𝗲𝗿 𝟮𝟱 𝘆𝗲𝗮𝗿𝘀 𝘄𝗲'𝘃𝗲 𝗵𝗮𝗱 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝟵𝟬% 𝗿𝗮𝘁𝗲 𝗼𝗳 𝘁𝗿𝗶𝗮𝗹 𝗳𝗮𝗶𝗹𝘂𝗿𝗲.

These age old infrastructures 𝘤𝘳𝘦𝘢𝘵𝘦 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗮𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝘃𝗲 𝘄𝗼𝗿𝗸, 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗰𝗼𝘀𝘁𝘀, 𝘀𝗹𝗼𝘄 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝗼𝗻. They make trials harder for sites, for patients, and for sponsors.

The results speak for themselves and it's simple:
Trials fail using age old tech and the so called "improvements" to old tech 𝘸𝘢𝘴𝘵𝘦𝘴 𝘮𝘪𝘭𝘭𝘪𝘰𝘯𝘴 𝘪𝘯 𝘳𝘦𝘴𝘰𝘶𝘳𝘤𝘦𝘴 𝘪𝘯𝘴𝘵𝘦𝘢𝘥 𝘰𝘧 𝘮𝘰𝘷𝘪𝘯𝘨 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘧𝘰𝘳𝘸𝘢𝘳𝘥.

𝗙𝗶𝘅𝗶𝗻𝗴 𝘁𝗵𝗲 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗯𝗲𝗵𝗶𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗺𝗶𝗴𝗵𝘁 𝗯𝗲 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗶𝘁.

01/09/2026

𝗪𝗵𝗮𝘁 𝗶𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗵𝗮𝗱 𝗮 𝘀𝗲𝗮𝘁 𝗮𝘁 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲 𝗯𝗲𝗳𝗼𝗿𝗲 𝘁𝗵𝗲 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹 𝘄𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻? 𝗪𝗲 𝗺𝗮𝗸𝗲 𝘁𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻.

Research suggest that designing trials that truly align with 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝗲𝘀 have benefits that are far reaching.

Listening to the everyday physical and logistical needs makes study participation seamless and accessible.

Trials built with patient input tend to better reflect what participants can realistically sustain. This increases patient retention, transparency, and participant compliance to the protocol throughout a trial.

Building strong trial infrastructure starts with listening from day one, turning valuable patient feedback into practical operational workflows 𝗯𝗲𝗳𝗼𝗿𝗲 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 𝗮𝗿𝗲 𝗱𝗲𝗰𝗶𝗱𝗲𝗱.

𝗣𝗲𝗼𝗽𝗹𝗲 𝗮𝗿𝗲 𝗲𝗮𝗴𝗲𝗿 𝘁𝗼 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗲 𝗶𝗻 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵. 𝗢𝘂𝗿 𝗴𝗼𝗮𝗹 𝗶𝘀 𝗲𝗻𝘀𝘂𝗿𝗶𝗻𝗴 𝘁𝗿𝗶𝗮𝗹 𝗱𝗲𝘀𝗶𝗴𝗻𝘀 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗮𝗻𝗱 𝗲𝗺𝗽𝗼𝘄𝗲𝗿 𝘁𝗵𝗲𝗺 𝗲𝘃𝗲𝗿𝘆 𝘀𝘁𝗲𝗽 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗮𝘆.

Find out more below.

28/08/2026

𝗧𝗶𝗺𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗶𝗻 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻'𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲. 𝗕𝘂𝘁 𝗻𝗼𝘁 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗴𝗲𝘁𝘀 𝗮𝗻 𝗲𝗮𝗿𝗹𝘆 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀.

For many African Americans, Parkinson's is typically diagnosed later, despite the importance of early recognition and treatment.

Research suggests this is driven by a combination of factors, including barriers to specialist care, bias in healthcare, and the historic underrepresentation of Black communities in clinical research.

Why does this matter?

• 𝗘𝗮𝗿𝗹𝗶𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗰𝗮𝗻 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝘀𝘆𝗺𝗽𝘁𝗼𝗺 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 & 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗹𝗶𝗳𝗲.

• 𝗠𝗼𝗿𝗲 𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝘃𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗲𝗹𝗽𝘀 𝘂𝘀 𝗯𝗲𝘁𝘁𝗲𝗿 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝗵𝗼𝘄 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻'𝘀 𝗮𝗳𝗳𝗲𝗰𝘁𝘀 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀.

• 𝗕𝗿𝗼𝗮𝗱𝗲𝗿 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗯𝘂𝗶𝗹𝗱𝘀 𝘀𝘁𝗿𝗼𝗻𝗴𝗲𝗿 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗯𝗲 𝗮𝗽𝗽𝗹𝗶𝗲𝗱 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝘁𝗹𝘆 𝗮𝗰𝗿𝗼𝘀𝘀 𝗮𝗹𝗹 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝗶𝗲𝘀.

When some communities are consistently underrepresented in research, gaps remain in the evidence that informs diagnosis, treatment, and care. Improving representation helps ensure future medicines and healthcare decisions are supported by evidence that reflects the people they are intended to serve.

If you'd like to learn more about Parkinson's research or opportunities to participate in future clinical studies, visit our Communities page or contact us at [email protected]

27/08/2026

𝗪𝗵𝘆 𝗱𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝘀𝘁𝗮𝗿𝘁𝘂𝗽 𝗱𝗲𝗹𝗮𝘆𝘀 𝘀𝘁𝗶𝗹𝗹 𝗵𝗮𝗽𝗽𝗲𝗻 𝗶𝗻 𝟮𝟬𝟮𝟲, 𝗲𝘃𝗲𝗻 𝘄𝗶𝘁𝗵 𝗿𝗲𝗰𝗼𝗿𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆?

Usually it's not a lack of tools. It's 𝗳𝗿𝗮𝗴𝗺𝗲𝗻𝘁𝗲𝗱 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀 from years of adopting disconnected solutions.

𝗧𝗵𝗲 𝗿𝗶𝘀𝗸𝘀 𝗮𝗱𝗱 𝘂𝗽 𝗳𝗮𝘀𝘁: delays, duplicate work, and blind spots that can cause costly protocol deviations and compliance issues.

Our Chief Operations Officer, Aleksandra Barabasz, shares the opportunity of using a unified AI-native system like R.grid to eliminate 𝗵𝗶𝗱𝗱𝗲𝗻 𝗮𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝘃𝗲 𝗯𝗼𝘁𝘁𝗹𝗲𝗻𝗲𝗰𝗸𝘀.

With R.grid AI every solution can fill a pre-existing gap or become a unified system bespoke to meet your needs. Find out more about our solutions in the link below.

R.grid

22/09/2026

21/09/2026

18/09/2026

10/09/2026

09/09/2026

08/09/2026

03/09/2026

01/09/2026

28/08/2026

27/08/2026

Address

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category

Listing takedown request